

Investor Newsletter

Issue **05** 2015



Shanghai MicroPort Orthopedics Hosts First SuperPath™ Online Symposium

Shanghai MicroPort Orthopedics Co ("Shanghai MicroPort Orthopedics") recently hosted its first online symposium of SuperPath™ Micro-posterior Total Hip Arthroplasty ("THA") Surgical Technique.

Four international and domestic experts were invited to share their surgical experience with SuperPath™, including Dr. Jimmy Chow of US-based St. Luke's Medical Center, Professor Yunsu Chen of Shanghai Sixth People's Hospital, Baolin Li of Guangzhou Orthopedic Hospital, and Yanguo Qin of the Second Hospital of Jilin University. The symposium was live broadcasted on allinmd.cn, an exchange platform for orthopedic surgeons, which attracted 1,554 surgeons to view online.

Dr. Jimmy Chow, who has performed over 1,000 THA surgeries using SuperPath™ Hip technique, answered frequently asked questions for beginners with SuperPath™. He noted, SuperPath™ surgical technique can be used on most patients who are suitable for traditional hip replacement, but patients with soft tissue contracture or rigidity should be carefully evaluated whether he is suitable to use SuperPath™ or not.

The other three experts provided practical tips for SuperPath™ THA. For instance, Professor Yunsu Chen presented some surgical skills to use PROFEMUR® Classic Z Hip Stem in SuperPath™ THA; Professor Baolin Li talked about how to use SuperPath™ to preserve bone fractures; and Professor Yanguo Qin explained why it is easy to convert a traditional posterior hip approach to a SuperPath™ hip procedure – it does not need any special equipment such as operation table, and MicroPort Orthopedics provides a full set of surgical tools for SuperPath™ THA.

The SuperPath™ technique is a tissue-sparing procedure which aims to get patients back on their feet within days (possibly hours) instead of weeks or months. With SuperPath™, there is no surgical dislocation of the hip. Patients can also have as little as a 3-inch incision. Because of the elimination of damage to the important structures during reconstruction, patients typically have a short hospital stay and a number of patients walk the same day as their surgery. Such surgical technique is gaining higher market recognition world-wide with the growing demand of joint replacement surgeries.



TKA Surgical Observation in Belgium

From April 19 to April 23, Shanghai MicroPort Orthopedics invited four Chinese experts to attend the TKA surgery observation of Evolution® in Belgium. The event mainly focused on the discussing design rationale, clinical outcome and surgical technique of the medial-pivot knee system.



Medial-pivot knee system features a “ball in socket” in medial side, on the lateral side there is arcuate path, which allows 15° of motion around a medial-pivot point. It can restore the anatomy and kinematics of a natural knee, which is an important revolution in the TKA history. Over 370,000 medial-pivot knee systems were implanted since it was launched in 1998, and the good clinical outcome was highly recognized by both surgeons and patients.

The event lasted for three days, during which four Chinese orthopedic experts visited two hospitals in Ghent and Antwerp and met with three Belgium experts to have surgical observation and discussions. They observed 10 cases, including nine Evolution® Primary TKAs and one Advance® Revision TKA. Each of them had the opportunity to scrub in and watch the surgeries clearly.

Orthopedic experts from China and Belgium had good communications about their own experience with Advance® and Evolution® Medial-pivot Knee. They also discussed the mutual benefits and differences between these two systems. They highly recognized the clinical outcome of medial-pivot knee and agreed that Evolution® system ensures post-operative stability, provides faster recovery after surgery, is easy to use and can meet different needs of patients and surgeons with three sets of complete systems.

As the second generation of MicroPort’s medial-pivot knee, Evolution® will be launched in China in July, 2015. We hope this successful TKA surgical observation will help pave the way for its launch.



Evolution® Product Meeting

MicroPort Orthopedics Japan held the Evolution® Product meeting in the Keio University Hospital, one of major hospitals in Tokyo. About 20 surgeons from the hospital attended the meeting. The Associate Manager of Knee Product, made a presentation on Evolution® Knee, and later a workshop was held to further explain its features. The company is planning to carry out a clinical study with the hospital and this event helped the surgeons to gain deeper understanding in the products. Many questions were raised by the attendees and the meeting turned out to be a great success.



JOA 2015

The 88th Annual Meeting of the Japanese Orthopedic Association ("JOA") was held from May 21 to May 23 in Kobe city which is located in West Japan. This is the biggest Japanese annual orthopedic event and more than 10,000 people attended. This year, our booth was designed to look sophisticated and also to allow people to feel free to visit. Samples of SuperPath™ and Evolution® which we focus on in our business were displayed at the center of the booth.

The sales representatives and marketing team felt Medial Pivot concept was far more recognized than before as they received many questions about it. In Japan new ideas like SuperPath™, with the concept of fast recovery, is not easily accepted partly because people in Japan tend to stay at hospital after surgery until they feel comfortable to leave using the national health insurance. In any case, it drew attentions from our visitors during the JOA. We received about 250 questions and requests from our customers at the booth and also had many productive meetings with surgeons to move our plans forward. It was a very successful event.

Firehawk® and WILLIS® Proved Cost-effective


Two medical devices of Shanghai MicroPort Medical (Group) Co ("MicroPort") - Firehawk® Rapamycin Target Eluting Coronary Stent System and WILLIS® Intracranial Stent Graft System - were proved to have relatively high cost-effectiveness, according to official health economic evaluation results recently released.

On April 24, experts announced the health economic evaluation results of Firehawk® and WILLIS®, products respectively developed by MicroPort and its subsidiary MicroPort NeuroTech, in an experience-sharing meeting of centralized procurement of disposable medical supplies, organized by China Association of Medical Equipment.

During the meeting, Dr. Xiaohua Ying, Professor of Public Health School of Fudan University and Deputy Director of Key Lab of Health Technology Assessment of the Ministry of Health, shared the evaluation results of Firehawk®. Specifically, Firehawk® has better therapeutic effect in treating patients with single coronary artery lesion in single vessel, compared to imported stents of the same price. Besides, in treating patients with single coronary artery lesion in single vessel, as long as Firehawk®'s price is no higher than 113% of the imported stents, every unit of incremental cost of Firehawk® brings more additional unit of the measure of effect.

Meanwhile, Dr. Jianwei Xuan, Professor of Florida State University, Advisory Professor of Public Health School of Fudan University, Research Fellow of the Research Center of National Drug Policy & Ecosystem, and President of Advisory Committee of Asia-Pacific Branch of International Society for Pharmacoeconomics and Outcomes Research, explained the assessment results of WILLIS®. It showed, compared with coil embolization treatment, WILLIS® has higher clinical efficacy and lower overall cost.

In the future, health economic evaluation will provide important decision rules for China's pricing and purchasing policies. Unlike traditional assessment methods that only focus on the safety and effectiveness of a medical product, health economic studies evaluate both cost and effects, which better serve to guide optimal healthcare resource allocation.



MicroPort Attends EuroPCR 2015

MicroPort recently attended EuroPCR 2015, a world leading course in interventional medicine that was held in Paris, to present our in-development bioresorbable scaffold and to promote our Firehawk® to more patients around the world.

On May 19, a symposium was held to discuss innovative stents, co-chaired by Professor Runlin Gao, Chief Expert of Cardiology Department with the Fuwai Hospital and President of China Interventional Therapeutics ("CIT"), and C.K. Naber, an internationally renowned expert. In the symposium, Vice President of Fuwai Hospital Yuejin Yang introduced Firehawk®'s major features and the latest clinical outcome of Target trials. He shared his experience in using MicroPort products and spoke highly of the devices. Professor Yang also announced that MicroPort planned to launch a large-scale, randomized trial - TARGET ALL Comer - in Europe.

Meanwhile, Dr. Virmani, who serves as the President and Medical Director of CVPath Institute, introduced MicroPort's in-development bioresorbable scaffold to people in attendance, the first time for the new stent to appear in an international event. The bioresorbable scaffold features cutting-edge technologies including reduced scaffold thickness and Target Eluting technology with abluminal coating. Dr. Virmani released its six-month animal experimental results, which was positively received by the audience.

On May 21, the congress hosted a special session themed "Treating Left Main Complex Lesions with Percutaneous Coronary Intervention ("PCI")," co-chaired by Professor Runlin Gao and a French expert Dr. Morice. In the session, a surgery treating left main complex lesions with Firehawk® was broadcasted. The surgery was done by Professor Shaoliang Chen, a senior cardiologist of Nanjing First Hospital, and was well received by the attendees. Specifically, the patient was diagnosed with highly complex lesions involving LM, LAD and LCX, and calcification pervaded LCX. Syntax score was 31 and Syntax score II predicted that the mortality rate of applying PCI was lower than that of CABG. FFR showed 0.73, which indicated significant ischemia. Therefore, Professor Chen decided to predilate and then to implant two Firehawk® stents in LCX and LAD by using DK-Crush technique. IVUS and angiography showed TIMI flow 3 and the procedure was done successfully. The surgery once again proved Firehawk®'s safety and efficacy.

In the EuroPCR 2015, MicroPort was present with a booth which attracted much attention from surgeons and industry experts. Many of them showed interest in our products and had active interaction with our employees.

■ euro
PCR The leading
cardiovascular Course



VSD Occluder Gains CFDA Registration Certificate

Dongguan Kewei Medical Instrument Co ("Dongguan Kewei") received the registration certificate for its Ventricle Septal Defect Occluder ("VSD Occluder") from China Food and Drug Administration ("CFDA").

This product is designed for interventional treatment of congenital heart ventricle septal defect. Once placed in the lesion, the VSD Occluder effectively blocks abnormal blood flow so as to repair or rebuild the defect.

The VSD Occluder uses curved-surface double-umbrella design, which makes it more stable and unlikely to drop off. It is proved to be safe and reliable as it passes 400 million times of durability evaluation. It uses a special connection design and welding technology to reduce the risk of the occluder being disconnected from the delivery system in the delivery process. High-quality Nitinol material with intensive heating processing ensures its excellent superelasticity, biological compatibility and the ability of shape memorizing, which enables the occluder to deliver smoothly and to deploy completely when released.



Aside from the VSD Occluder, Dongguan Kewei also offers PDA Occluder, ASD Occluder and Occluder Delivery System, all with CFDA approval. With a more diversified product offering, Dongguan Kewei will provide better service to patients with congenital heart diseases.



MicroPort Hosts the Third Science and Technology Conference

On the occasion of its 17th Anniversary, MicroPort hosted its Third Science and Technology Conference on May 15 in Shanghai headquarters to share the latest developments of its on-going R&D projects and awarded several R&D talents.

At the beginning of the meeting, Dr. Qiyi Luo, Chief Technology Officer of MicroPort Scientific Corporation ("MPSC"), delivered a speech noting that MicroPort will keep in step with the cutting-edge developments of the medical industry, such as telemedicine, personalized medicine, smart healthcare and automated healthcare, to develop technologies and products aimed at improving patient's life quality. Dr. Luo also encouraged MicroPort's R&D staffs to take advantage of our Research & Engineering Academy that was launched in last May to develop more medical devices with independent intellectual property rights. ▶

Afterwards, 17 project teams from MicroPort R&D Department, MicroPort Endovascular, MicroPort Orthopedics, MicroPort EP, MicroPort NeuroTech, D-Pulse Medical, MicroPort Sorin CRM and Dongguan Kewei, made presentations about the current and future developments of their projects. The introductions were followed by an active Q&A session which stimulated both the audience and speakers.

In the award session, Dr. Zhaohua Chang, MPSC Chairman and CEO, and Dr. Luo gave out certificates of honor to 22 young talents and seven project leaders. Meanwhile, eight project teams received awards for Excellent Project Presentation and several patent inventors were awarded patent certificates.

Dr. Chang said, MicroPort was well-known for its talent management and will continue its way to select and cultivate talents. He expressed the hope that every MicroPort employee would use his or her wisdom to create more economic benefits to the company and bring better service to patients and surgeons.





MicroPort Hosts 2015 Annual Distributor Conference


MicroPort hosted 2015 Annual Distributor Conference on May 14 in its Shanghai headquarters to promote its products to nationwide distributors. About 400 distributors attended the meeting.

During the event, brief introductions of MicroPort's devices, such as PROFEMUR™ Classic Z Hip Stem, PROPHECY™ Pre-Operative Navigation System, Occluder, REPLY DR/D/VDR/SR Peacemaker, La Fenice® Insulin Pump, Firestone® Cervical Fusion Device, Castor Thoracic Branch Stent-Graft System, Columbus™ 3D EP Navigation System, Firehawk® Rapamycin Target Eluting Coronary Stent System, WILLIS® Intracranial Stent Graft System, and APOLLO Intracranial Stent System, were presented to people in attendance. These products cover a wide range of business segments including cardiovascular, orthopedic, electrophysiological, endovascular, neurovascular, surgical and diabetes care and endocrinal management. ▶

In the meeting, MicroPort also gave out several awards to 20 of its distributors, including Partner of the Best Contribution of the Year, Partner of the Best Sincerity of the Year, Partner of the Best Diversification of the Year, and Gold Certified Partner of the Year, to appreciate their trust and confidence in MicroPort.

"With a rapidly increasing product offering and continuously expanding overseas markets, we believe that there are boundless opportunities in all of MicroPort's business segments," said Bo Peng, Chief Marketing Officer and Chairman of Greater China Executive Committee of MPSC, "MicroPort will keep bringing more innovative products to patients and surgeons, and we are looking forward to seeing more distributors join us and build an even more successful future together."





MicroPort Promotes Cardiovascular Devices

From April 24 to April 26, MicroPort attended the 18th China Cardiovascular Intervention Forum that was held in Guiyang of Guizhou Province. During the event, we promoted our cardiovascular products – Firehawk® and Pioneer™ PTCA Balloon Dilatation Catheter – to people in attendance. Meanwhile, MicroPort carried out a customer satisfaction survey on our cardiovascular products and six experts were invited to give suggestions in terms of product performances and market service.



MicroPort Attends Cardiovascular Summit TCTAP

From April 28 to May 1, the 20th Cardiovascular Summit TCTAP 2015 was held in Seoul of South Korea, which attracted more than 4,000 industry experts from over 50 countries. MicroPort is China's first medical device company to participate in the event. It hosted a "Live Case Session V-China" in which several cardiovascular surgeons were invited to complete a left main bifurcation lesion surgery. During the conference, MicroPort International Business staffs had discussions with South Korean distributors about how to further expand the local market.

MicroPort Attends CMEF

From May 15 to May 18, China International Medical Equipment Fair (“CMEF”), Asia Pacific’s leading event serving the entire value chain for the medical device market, was held in Shanghai. MicroPort and its subsidiaries Shanghai MicroPort Orthopedics and Dongguan Kewei attended the congress. We presented our products and brands to people in attendance to seek potential distributors.



Round Table of Consulate-General of Israel in Shanghai

On April 28, MPSC CTO Dr. Luo was invited by the Consulate-General of Israel in Shanghai to attend a Round Table, in which he discussed the latest development of medical industry with a group of industry leaders.

MicroPort Endovascular Attends Vascular Forum

From May 21 to May 23, the First Northeast China Vascular Forum was held in Shenyang, Liaoning Province. MicroPort Endovascular attended the meeting to promote our products. Castor Branched Aortic Stent Graft System was highly recognized by surgeons in attendance.

Free Clinic

On May 19, Shanghai MicroPort Orthopedics launched a free clinic in Zhejiang Provincial People's Hospital, which attracted around 150 local residents in Hangzhou. Orthopedic surgeons from Zhejiang Provincial People's Hospital were invited to lecture on the main causes of hip diseases and how to prevent and treat the disease. Attendees also received free consulting and diagnose service after the training.



Investor Newsletter

Issue **05** 2015



For more information, please contact:

Hongbin Sun

Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com

Xun You

Board Secretary
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600

Email: ir@microport.com